MetaCap

Rafael (RFL) vs Verrica Pharmaceuticals (VRCA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Rafael (RFL) has outperformed Verrica Pharmaceuticals (VRCA) over the past year, losing 25.8% versus a loss of 34.9%. Over five years, RFL leads with a -84.2% price change compared with -97.4% for VRCA. Rafael is the larger company by market cap ($48.0 million vs $47.1 million), about 1.0 times the size, while Verrica Pharmaceuticals is growing revenue faster (+370.2% vs -4.7%).

Verrica Pharmaceuticals converts more of its revenue into profit, with a net margin of -50.3% versus -3390.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

RFL-25.83%VRCA-34.92%
+217%+85%-47%
Nov 21, 20251 yearNov 20, 2026
RFL-84.64%VRCA-97.60%
+5%-49%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

RFL versus VRCA key metrics
MetricRFLVRCA
Share price$0.9197$2.74
Market cap$47.99M$47.07M
1-day change+2.19%-5.03%
YTD return-22.06%-67.03%
1-year return-25.83%-34.92%
5-year return-84.19%-97.38%
EPS (TTM)$-0.58$-2.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$874.00K$35.58M
Revenue growth (YoY)-4.69%+370.22%
Net income (latest FY)$-29.64M$-17.89M
Operating margin-3822.54%-34.25%
Net margin-3390.73%-50.27%
52-week high$3.96$9.82
52-week low$0.781$2.73
Distance from 52-week high-76.78%-72.10%
Analyst consensus—strong_buy
Avg. price target upside—+404.74%
Average volume140.84K68.78K
Shares outstanding51.39M17.18M
Employees2176
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Verrica Pharmaceuticals is more profitable, keeping -50.3 cents of every revenue dollar as net income versus -3390.7 cents for Rafael.
  • Verrica Pharmaceuticals grew revenue faster in its latest fiscal year (+370.22% vs -4.69%).

About Rafael

RFL stock →

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.

Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees

About Verrica Pharmaceuticals

VRCA stock →

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

RFL vs VRCA FAQ

Which is bigger, Rafael or Verrica Pharmaceuticals?

Rafael (RFL) is larger, with a market capitalization of $47.99M compared with $47.07M for Verrica Pharmaceuticals (VRCA).

Which stock has performed better over the past year, RFL or VRCA?

RFL returned -25.83% over the past 12 months, compared with -34.92% for VRCA (price return, excluding dividends). Past performance does not predict future results.

Are Rafael and Verrica Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons